ProductLife Group Acquires Global Regulatory Outsourcing Company
ProductLife Group (PLG, Paris, France) has announced the acquisition of ELC Group, a Czech Republic-based regulatory consulting firm with 150 employees.
The strategic merger with ELC comes two months after the acquisition of US-based regulatory drug development consultancy DSI and helps to further accelerate the execution of PLG’s strategic plan, BoOst 2023, which aims to make PLG the worldwide leader in regulatory affairs and compliance. The new group will now include more than 600 staff members located in 40 countries.
“This is a landmark acquisition for PLG that complements our domain expertise and brings enhanced capabilities to our solutions, enabling us to provide sustainable business value to our clients. Adding offshore delivery capability in such a key location as India expands our ability to meet this goal,” commented Xavier Duburcq, PLG CEO.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
